Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels

              Author:Pardo, Gabriel   Kappos, Ludwig   Cross, Anne   Kuhle, Jens   Montalban, Xavier   Khachanova, Natalia   Bhatt, Alit   Piccolo, Rebecca   Xi, Jing   Boer, Ibolya   Arnold, Douglas   Alvarez, Enrique   Ziemssen, Tjalf   

              Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

              Topic:Multiple Sclerosis  

              Program Number:P9.008  

              Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK  RC2NB, University Hospital Basel, Basel, Switzerland  Washington University School of Medicine, Clayton, MO  Neurologic Clinic and Policlinic and MS Center, Basel, Switzerland  Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, Barcelona, Spain  Russian National Research Medical University N.I. Pirgov, Moscow, Russian Federation  Novartis Healthcare Pvt. Ltd, Hyderabad, India  Novartis Pharmaceuticals Corporation, West Roxbury, MA  Novartis, Shanghai, China, People's Republic of  Novartis Pharma AG, Basel, Switzerland  Montreal Neurological Institute, McGill Univ, Montreal, QC, Canada  University of Colorado, Aurora, CO  University Clinic Dresden, Dresden, Germany  

              Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies

              Author:Robertson, Derrick   Hartung, Hans-Peter   Arnold, Douglas   Lee, Lily   Gocke, Anne   Mok, Koby   Alvarez, Enrique   

              Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

              Topic:Multiple Sclerosis  

              Program Number:P9.017  

              Author Institution:University of South Florida, Tampa, FL  Heinrich Heine University Medical Faculty , Dusseldorf, Germany  Montreal Neurological Institute, McGill Univ, Montreal, QC, Canada  TG Therapeutics, New York, NY  TG Therapeutics, Seal Beach, CA  University of Colorado, Aurora, CO